InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Discover the complete record of transactions filed by HANNAH ALISON L., Director. Officer active across 4 companies, notably Neogenomics INC. Cumulatively, 10 disclosures have been recorded. The latest transaction was disclosed on 1 June 2025 — Levée d'options. Regulator: SEC (Form 4). The full history is free.
Declarations10 total
012,254 shares0
Common Stock
SEC:0001077183-25-000132·
012,254 shares0
Common Stock
SEC:0001077183-25-000132:0·
015,556 shares0
Common Stock
SEC:0001077183-22-000110:0·
025,000 shares0
Common Stock
SEC:0001140361-22-020304:0·
022,500 shares0
Common Stock
SEC:0001567619-22-002523·
022,500 shares0
Common Stock
SEC:0001567619-22-002523:0·
03,081 shares0
Common Stock
SEC:0001077183-21-000162·
03,081 shares0
Common Stock
SEC:0001077183-21-000162:0·
06,250 shares0
Common Stock
SEC:0001179110-21-005772·
06,250 shares0
Common Stock
SEC:0001179110-21-005772:0·
10 of 10 declarations
About HANNAH ALISON L.
Alison L. Hannah is a Board Member and Chief Medical Officer at NEOGENOMICS INC and RIGEL PHARMACEUTICALS INC. She oversees medical affairs and contributes to the company's strategy. Hannah plays a key role in innovation and the development of new treatments.
